Romosozumab increases bone mineral density in Japanese older adults with osteoporosis

This study aimed to evaluate the efficacy of romosozumab in older Japanese patients with osteoporosis.

Bone mineral density (BMD) was measured at 0, 4, 6, and 12 months after romosozumab treatment.

Of 125 patients with osteoporosis (mean age: 77.6 ± 7.5 years), 115 completed BMD measurements at the lumbar spine, total hip, and femoral neck. The BMD at the lumbar spine (11.5%, P < .01), total hip (3.0%, P < .01), and femoral neck (3.7%, P < .01) increased 12 months after treatment. There were no differences in the improvement ratio of BMD after 12 months of treatment at the lumbar spine, total hip, and femoral neck among 76 patients aged ≥75 years and 39 aged <75 years (11.0% vs. 12.5%: P = .48, 3.0% vs. 3.0%: P = .83, 3.6% vs. 4.1%: P = .92), 48 with prior treatment of osteoporosis and 67 without prior treatment of osteoporosis (10.8% vs. 12.1%: P = .56, 2.1% vs. 3.7%: P = .25, 2.8% vs. 4.5%: P = .61), and 55 patients with a history of fragility fracture and 60 without a history of fragility fracture (11.8% vs. 11.3%: P = .88, 2.4% vs. 3.5%: P = .51, 2.0% vs. 5.3: P = .11).

Romosozumab improved BMD at the lumbar spine, total hip, and femoral neck in older adults with osteoporosis.